353 related articles for article (PubMed ID: 22056033)
1. Abnormal granulation of blood granulocytes in mucopolysaccharidosis VI-a case report.
Krishnagiri C; Ajanahalli RR; Kashyap S; Anegundi R; Boranaik L
Ann Diagn Pathol; 2013 Feb; 17(1):137-9. PubMed ID: 22056033
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
Harmatz P
Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
[TBL] [Abstract][Full Text] [Related]
3. [Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy].
Politei J; Schenone A; Blanco M; Szlago M
Arch Argent Pediatr; 2014 Jun; 112(3):258-62. PubMed ID: 24862809
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of clinical features and arylsulfatase B gene mutation in thirteen Chinese children with mucopolysaccharidosis type VI].
Zheng J; Huang Y; Zhao X; Sheng H; Cheng J; Zhou Z; Li X; Mao X; Liu L
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):403-8. PubMed ID: 25190157
[TBL] [Abstract][Full Text] [Related]
5. Thrombocytopenia associated with galsulfase treatment.
Doğan M; Cesur Y; Peker E; Oner AF; Dogan SZ
Hum Exp Toxicol; 2011 Jul; 30(7):768-71. PubMed ID: 20670992
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
7. A Desensitization Method to Maintain Enzyme Replacement Therapy in Mucopolysaccharidosis Type VI.
Kör D; Şeker Yilmaz B; Bulut FD; Önenli Mungan N; Ufuk Altıntaş D
J Investig Allergol Clin Immunol; 2016; 26(2):130-2. PubMed ID: 27164636
[No Abstract] [Full Text] [Related]
8. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
9. Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy.
Koseoglu ST; Harmatz P; Turbeville S; Nicely H
Int Ophthalmol; 2009 Aug; 29(4):267-9. PubMed ID: 18418554
[TBL] [Abstract][Full Text] [Related]
10. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
[TBL] [Abstract][Full Text] [Related]
11. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.
Di Natale P; Villani GR; Parini R; Scarpa M; Parenti G; Pontarelli G; Grosso M; Sersale G; Tomanin R; Sibilio M; Barone R; Fiumara A
Biotechnol Appl Biochem; 2008 Mar; 49(Pt 3):219-23. PubMed ID: 17672828
[TBL] [Abstract][Full Text] [Related]
12. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.
Turner CT; Hopwood JJ; Bond CS; Brooks DA
Mol Genet Metab; 1999 Jul; 67(3):194-205. PubMed ID: 10381327
[TBL] [Abstract][Full Text] [Related]
13. Mucopolysaccharidosis VI.
Valayannopoulos V; Nicely H; Harmatz P; Turbeville S
Orphanet J Rare Dis; 2010 Apr; 5():5. PubMed ID: 20385007
[TBL] [Abstract][Full Text] [Related]
14. Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry.
Crawley A; Ramsay SL; Byers S; Hopwood J; Meikle PJ
Pediatr Res; 2004 Apr; 55(4):585-91. PubMed ID: 14711884
[TBL] [Abstract][Full Text] [Related]
15. Corneal hysteresis in mucopolysaccharidosis I and VI.
Fahnehjelm KT; Chen E; Winiarski J
Acta Ophthalmol; 2012 Aug; 90(5):445-8. PubMed ID: 21232085
[TBL] [Abstract][Full Text] [Related]
16. Maroteaux-Lamy syndrome.
Lakhotia S; Sharma A; Shrivastava GP; Jain SK
Indian J Pediatr; 2004 Oct; 71(10):933-5. PubMed ID: 15531839
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats.
Auclair D; Finnie J; Walkley SU; White J; Nielsen T; Fuller M; Cheng A; O'Neill CA; Hopwood JJ
Pediatr Res; 2012 Jan; 71(1):39-45. PubMed ID: 22289849
[TBL] [Abstract][Full Text] [Related]
18. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
Giugliani R; Lampe C; Guffon N; Ketteridge D; Leão-Teles E; Wraith JE; Jones SA; Piscia-Nichols C; Lin P; Quartel A; Harmatz P
Am J Med Genet A; 2014 Aug; 164A(8):1953-64. PubMed ID: 24764221
[TBL] [Abstract][Full Text] [Related]
19. [Maroteaux-Lamy syndrome: a case report].
Mtar A; Charfeddine B; Braham I; Ben Abdallah J; Neffati S; Smach MA; Bourfifa Z; Ksouri M; Dridi H; Limem K
Ann Biol Clin (Paris); 2011; 69(6):693-7. PubMed ID: 22123570
[TBL] [Abstract][Full Text] [Related]
20. Up to five years experience with 11 mucopolysaccharidosis type VI patients.
Brands MM; Oussoren E; Ruijter GJ; Vollebregt AA; van den Hout HM; Joosten KF; Hop WC; Plug I; van der Ploeg AT
Mol Genet Metab; 2013 May; 109(1):70-6. PubMed ID: 23523338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
